Vantavo (previously Alendronate sodium and colecalciferol, MSD) (alendronic acid;colecalciferol)
- Region
- 🇪🇺 EU
- Active substance
- alendronic acid;colecalciferol
- Company
- Organon N.V.
- Status
- Authorised
- Therapeutic area
- Osteoporosis, Postmenopausal
- CHMP opinion
- Thu 23 Jul 2009
- EU approval
- Fri 16 Oct 2009
- Application
- EMEA/H/C/001180
- ATC
- M05BB03
- Official record
- www.ema.europa.eu
Indication
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures. Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Adrovance Authorised · Organon N.V.
- 🇪🇺 Fosavance Authorised · Organon N.V.
Follow Vantavo (previously Alendronate sodium and colecalciferol, MSD)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.